Fluoxetine Induced Akathisia - a Case Report Vinay Gupta1

Total Page:16

File Type:pdf, Size:1020Kb

Fluoxetine Induced Akathisia - a Case Report Vinay Gupta1 Indian J. Psychiat., 1992,34(3), 27S-279 FLUOXETINE INDUCED AKATHISIA - A CASE REPORT VINAY GUPTA1 Akathisia is a common side-effect of the amitriptyline, nitroxazepine given along with neuroleptic drugs and occurs in about 5% to lithium, low doses of haloperidol and 75% cases treated with these compounds (Bar­ thioridazine, in different combinations. How­ nes et al., 1985; Van Putten et at., 1984). In ever not all drugs were precribed in adequate addition, akathisia like syndromes are doses and for sufficient length of time to actual­ produced with conditions such as uremia, ly call him resistant to treatment with these idiopathic restless legs syndrome, congestive compounds. He was prescribed fluoxetine in heart failure, idiopathic parkinsonism, and with view of its established efficacy in OCD and also drugs such as reserpine, .trycyclic antidepres­ in depressive illness. sants (Gibb et al., 1986; Zubenko et al., 1987) and diltiazem. Two weeks later when he came for his scheduled follow up, he was not taking In 1978, Zitrin et alreported that 18% of fluoxetine, as he reported to have their cases in a series of patients with phobias, developed marked restlessnes, anxiety, in­ treated with imipramine developed a syndrome somnia, inability to sit still on the 5th day of characterised by "insomnia, jitteriness ir­ medication with 20mg/day morning dose of ritability and unusual energy" on dosage ranging fluoxetine. He was prescribed phenargan 25 from 5-75mg/day. This is quite similar to mg thrice a day by a local psychiatrist in his akathisia, a side-effect also reported with the city, whom he contacted with these com­ antidepressant fluoxetine by Lipinski et al. plaints, and he felt relieved of these (1989). symptoms within two days. A single case report of akathisia as a. On this follow up visit he had no such side-effect with fluoxetine is being discussed complaints and he had been off medicines for below. almost 8 days. He was reassured and advised to restart fluoxetine 20mg/day, considering his CASE HISTORY complaints to be temporary side-effects with the drug, which would pass off after a few days. A 22 year old unmarried, north Indian On the 6th day, he was back in the hospital, very male, visited our hospital clinic, with 3 year anxious, restless, jittery, and unable to keep his illness history, diagnosed as obsessive com­ legs still, and unable to sit still, with an urge to pulsive disorder (OCD) with secondary move about with which he felt better. The sub­ depression. He was put on Fluoxetine, start­ jective experience and his appearance sug­ ing with 20mg/day along with bed time gested the possibility of akathisia which is not diazepam 5mg. He had been drug free for mentioned as a side-effect in the product almost 15 days, and prior to this he had been monograph of fluoxetine, but anxiety, nervous­ treated with a variety of antidepressants, ness and insomnia is reported in about 10%- alone and in combination with other 15% of treated patients (Stark et al., 1985). psychopharmacological agents. He seemed to There was no sign of parkinsonism or dystonia have been unresponsive to imipramine, or any other finding on examination. 1 Lecturer, Department of Psychiatry, Christian Medical College, Ludhiana -141001. FLUOXETINE INDUCED AKATHISIA 279 He was then advised diazepam Lipinski et al., have suggested the prob­ lOmg/day along with propranolol 40mg/day ad­ able patho-physiology of fluoxetine induced ditionally, both in three divided doses, with akathisia. Akathisia follows the inhibition of which he felt better around 2nd & 3rd day, with dopaminergic neilrone in the Ventral tegmental symptoms reappearing on discontinuation of area (VTA). Fluoxetine and other compounds these. He was later shifted to imipramine that enhance serotonergic transmission (in­ therapy and fluoxetine was totally discontinued cluding Tricyclic anti-depressants (TCA'S) and because the patient refused to continue to take Mono-amine Oxidase Inhibitor's (MAOI'S)) it. produce akathisia, by enhancing serotonergi- cally mediated inhibition of Dopamine (DA) cells in the VTA, producing DA defiency and thus akathisia (Lipinski et al., 1989). DISCUSSION The case report is relevant because of Review of the literature on fluoxetine the recent introduction of fluoxetine in the In­ brought to light a paper by Lipinski et al. (1989), dian market. Combination of fluoxetine with a reporting 5 cases of akathisia induced by neuroleptic compound may increase the risk of fluoxetine. Three out of these five cases developing akathisia with fluoxetine. Moreover developed akathisia on the 5th day on 60 mg/day controlled prospective studies to determine its of fluoxetine, one within 12 hours on 20mg/day true incidence can be carried out. and the 5th after hours on a dose of 40mg/day. Fluoxetine induced akathisia is indistin­ guishable from neuroleptic akathisia, but is REFERENCES milder, and usually comes around the 5th day. Tolerance may develop to it, but it is relieved by Barnes, T.R.F. and Braudc, W.M. (1985). Akathisis variant either decreasing the dose of fluoxetine or ad­ and tardive dyskinesia. Arch Gen. Psychiatry, 42,874-878. ministration of propranolol, an adnergic recep­ Glbb, W.R.G. and Lees, AJ. (1986). The restless leg tor antogonist. Akathisia in these cases is not syndrome. Post. Grad. Med. J., 62,329-333. associated with signs and symptoms of parkin­ Lipinski, J.F.; Keck, P.F. and McElory, S.L. (1988). B- adrenergic antagonists in Psychosis: Is improvement due to sonism or dystonia, which almost always accom­ treatment of neuroleptic induced akathisia, clinical and pany neuroleptic induced akathisia. Figures of theoretical implications. J. Clin Psychiatry, 50,9, 339-342. its exact incidence have to be worked out but is Lipinski, J.F.; Mallya, G.; Zimmerman, R.N. and Har­ estimiated to be between 9.8% - 25% (Lipinski rison, G.P. (1989). Fluoxetine - induced akathesia, Clinical era/., 1989). and theoritical implications. J.Clin. Psychiatry, 46(3, sec 2), Stark, P.; Fuller, R.W. and Wong, D.T. (1985). The phar­ The tricyclic induced jitteriness macologic profile fluoxetine. J.Clin. Psychiatry. 46(3, Sec syndrome is identical to the syndrome 2), 7-13. produced by fluoxetine and both are clinically Van PiitUn, T.; May, P.R.A. and Marder, S.R. (1984). identical to akathisia (Zubencoefal., 1987)., The Akathisia with Haloperidol and thiothixene. Arch Gen. case history reported suggests akathisia as a Psychiatry, 41,1036-1039. side-effect of fluoxetine, since the patient was Zitrin, CM.; Klein, D.F. and Woerner, M.G. (1978). Be­ haviour therapy, supportive psychotherapy, imipramine drug free for over 2 weeks before institution of and phobias. Arch. Gen. Psychiatry, 35,307-31. fluoxetine which was not combined with any Zubenko, G.S.; Cohen, RM. and Lipinski, J.F. (1987). other drug likely to produce akathisia. Antidepressant- induced akathisia. J. Clin. Pcychophar- macol., 7,254-257. .
Recommended publications
  • WO 2012/148799 Al 1 November 2012 (01.11.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/148799 Al 1 November 2012 (01.11.2012) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/107 (2006.01) A61K 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A 61 47/10 (2006.0V) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, PCT/US2012/034361 HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 20 April 2012 (20.04.2012) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/480,259 28 April 201 1 (28.04.201 1) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant (for all designated States except US): BOARD UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, OF REGENTS, THE UNIVERSITY OF TEXAS SYS¬ TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, TEM [US/US]; 201 West 7th St., Austin, TX 78701 (US).
    [Show full text]
  • 2019 Instrumentation and Consumable Catalog 2 INSTRUMENTATION and CONSUMABLE CATALOG
    PRODUCT CATALOG 2019 Instrumentation and Consumable Catalog 2 INSTRUMENTATION AND CONSUMABLE CATALOG Resolvex® A200 Part Numbers: A200 96: 253-1160 Resolvex® A200 96 Resolvex A200 Standalone work station for automated sample preparation. The compact benchtop offers the one stop solution for automating sample preparation utilizing creation of multiple work flows, and programmable dispensing of up to 11 solvents. Along with its innovative positive pressure system leading to clean samples, improving accuracy, throughput and enhancing the Life time of your analytical instrument. The A200 comes with an easy to use touch screen interface allowing for easy set up of multiple work flows. In addition the light curtain safety feature will release gas pressure when manifold is activated to prevent any injuries. INSTRUMENTATION AND CONSUMABLE CATALOG 3 Resolvex® A100 Part Numbers: A100 96: 253-0019 A100 48: 253-0014 Resolvex® A100 Standalone work station for automated sample preparation. The compact benchtop offers the one stop solution for automating sample preparation utilizing creation of multiple work flows, and programmable dispensing of up to 11 solvents. Along with its innovative positive pressure system leading to clean samples, improving accuracy, throughput and enhancing the Life time of your analytical instrument. The A100 comes in 96 and 4 configuration allowing for for automated Work Flow solutions in multiple SPE formats. 4 INSTRUMENTATION AND CONSUMABLE CATALOG Resolvex® M10 96/M10 96 XT/M10 48 Part Numbers: M10 96 XT: 288-0006 M10 96: 288-0001 M10 48: 289-0004 Resolvex® M10 Standalone work station for Positive Pressure solid phase extraction. The manual Resolvex M10 48 and 96 are positive pressure manifold for 1, 3, and 6 ml cartridges, or 1ml 96 well plates.
    [Show full text]
  • Rp-Hplc Method for the Estimation of Nitroxazepine Hydrochloride in Pharmaceutical Dosage Forms
    Volume: I: Issue-3: Nov-Dec -2010 ISSN 0976-4550 RP-HPLC METHOD FOR THE ESTIMATION OF NITROXAZEPINE HYDROCHLORIDE IN PHARMACEUTICAL DOSAGE FORMS P.Sai Praveen1, B.Anupama*1, P.Sirisha2, Hanuma Reddy.Y3, T.V.B.Reddy4 1KVSR Siddhartha college of Pharmaceutical Sciences, Vijayawada-520010. 2GIET School of Pharmacy, Rajahmundry-533294 3Global college of Pharmacy 4Dept. of QA, Dr.Reddy’s Laboratories Ltd, Hyderabad ABSTRACT : A simple and sensitive isocratic RP‐HPLC method was developed for the determination of Nitroxazepine hydrochloride in bulk drug and its pharmaceutical tablet formulations where the mobile phase optimized was Phosphate buffer : Acetonitrile (70:30) and Phenomenex C18 column (250 mm length, 4.6 mm internal diameter and particle size 5 µm) was used as the stationary phase. The flow rate and detection wavelength was 1.0 mL min‐1 and 265 nm respectively. The developed method was validated as per ICH guidelines for specificity, linearity and range, precision, accuracy, robustness, limit of quantification and limit of detection. The results of all the validation parameters were well within their acceptance values. The method gave good recovery in the range of 98.95‐99.43 % for Nitroxazepine hydrochloride when it was applied for its determination in pharmaceutical tablet formulations. Keywords: Nitroxazepine hydrochloride, RP‐HPLC, Validation, Pharmaceutical formulation INTRODUCTION Nitroxazepine (Goodman and Gilman 1996, William O Foye 1989) chemically 10-[3- (dimethylamino) propyl-2-nitrobenzo [1,4] oxazepine-11(10H)-one, (Figure-1) is a major antidepressant drug (Jain AN et al. 1984, Bhatt AD et al. 1991). It is a tricyclic antidepressant (Balani ND et al.
    [Show full text]
  • 1 Supplemental Figure 1: Illustration of Time-Varying
    Supplemental Material Table of Contents Supplemental Table 1: List of classes and medications. Supplemental Table 2: Association between benzodiazepines and mortality in patients initiating hemodialysis (n=69,368) between 2013‐2014 stratified by age, sex, race, and opioid co‐dispensing. Supplemental Figure 1: Illustration of time‐varying exposure to benzodiazepine or opioid claims for one person. Several sensitivity analyses were performed wherein person‐day exposure was extended to +7 days, +14 days, and +28 days beyond the outlined periods above. 1 Supplemental Table 1: List of classes and medications. Class Medications Short‐acting benzodiazepines Alprazolam, estazolam, lorazepam, midazolam, oxazepam, temazepam, and triazolam Long‐acting benzodiazepines chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, flurazepam Opioids alfentanil, buprenorphine, butorphanol, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphine, meperidine, methadone, morphine, nalbuphine, nucynta, oxycodone, oxymorphone, pentazocine, propoxyphene, remifentanil, sufentanil, tapentadol, talwin, tramadol, carfentanil, pethidine, and etorphine Antidepressants citalopram, escitalopram, fluoxetine, fluvozamine, paroxetine, sertraline; desvenlafaxine, duloxetine, levomilnacipran, milnacipran, venlafaxine; vilazodone, vortioxetine; nefazodone, trazodone; atomoxetine, reboxetine, teniloxazine, viloxazine; bupropion; amitriptyline, amitriptylinoxide, clomipramine, desipramine, dibenzepin, dimetacrine, dosulepin, doxepin, imipramine, lofepramine, melitracen,
    [Show full text]
  • Info on Skin Testing
    Information on Skin Testing *Please review 1 week prior to testing* Your Doctor has ordered an allergy test for you. Your appointment has been made for: ___________________________________ at _______________________AM/PM at our (date) (time) _ Foulkstone / Limestone / Glasgow _ office. Skin tests are a method of testing for allergic reactions to substances, or allergens, in the environment. Our practice utilizes a test that involves no needles! We use a prick method which involves a series of small plastic applicators that carry a specific antigen which is placed on your arms. The types of allergens we test for include weeds, trees, grasses, molds, animal dander, dust mites and some foods. The testing will take 45 minutes. Please remember to wear comfortable clothing with short sleeves. Reactions can consist of itchy eyes, nose or throat, nasal congestion, runny nose, tightness in the throat or chest, wheezing, lightheadedness, hives or anaphylactic shock. Although this is very rare, our staff is fully prepared with emergency equipment and a physician is always on site. To ensure accurate testing results, certain medicines should be stopped 5 days prior to testing, although you should not stop medicines without talking to your prescribing physician. Medications that interfere with testing include but are not limited to: Antihistamines are medicines used to treat allergies, nausea, and dizziness. Many are found in over the counter cold medicines. They include, but are not limited to: ALAVERT / CLARITIN (LORATIDINE) DRAMAMINE (DIMENHYDRINATE)
    [Show full text]
  • Nitroxazepine | Medchemexpress
    Inhibitors Product Data Sheet Nitroxazepine • Agonists Cat. No.: HY-101684 CAS No.: 47439-36-1 Molecular Formula: C₁₈H₁₉N₃O₄ • Molecular Weight: 341.36 Screening Libraries Target: Serotonin Transporter Pathway: Neuronal Signaling Storage: Please store the product under the recommended conditions in the Certificate of Analysis. BIOLOGICAL ACTIVITY Description Nitroxazepine is a tricyclic antidepressant (TCA) for the research of depression. Nitroxazepine acts as a serotonin- norepinephrine reuptake inhibitor. IC₅₀ & Target serotonin-norepinephrine reuptake In Vitro The in vitro effect of Nitroxazepine (Sintamil), as a modulator alone and in combination with hydroxyurea (HU), on cytotoxicity is studied in 16 cases of human chronic myeloid leukemia (CML). The cytotoxicity of the drugs as a function of the exposure dose (HU, 100 μM; Nitroxazepine, 10 μg/mL) and the exposure time (1 h) to the agent is investigated. Cytotoxicity is evaluated as the inhibition of incorporation of [3H-methyl]thymidine in the nucleic acids of CML cells. Cytotoxicity of HU is greatly enhanced (P<0.001) by 1 h exposure of the CML cells to Nitroxazepine. The present data indicate that Nitroxazepine potentiates the cytotoxic activity of HU in CML cells[1]. Nitroxazepine is indicated for the treatment of nocturnal enuresis. Nitroxazepine has similar effects to imipramine, but with certain advantages, such as lower anticholinergic side effects. MCE has not independently confirmed the accuracy of these methods. They are for reference only. REFERENCES [1]. Pradhan SG, et al. Augmentation of hydroxyurea cytotoxicity by sintamil in human chronic myeloid leukemia cells. Tumori. 1986 Oct 31;72(5):507-10. McePdfHeight Caution: Product has not been fully validated for medical applications.
    [Show full text]
  • (3), Pp. 201-203 CLERICAL TRIAL of SINTAMIL and DOXEPIN HCL IN
    Indian journal of Pryihiatrj. July 19*6, 2»(3), pp. 201-203 CLERICAL TRIAL OF SINTAMIL AND DOXEPIN HCL IN DEPRESSED PATIENTS • "RK MAHENDRU •" S MAHENDRU Sintamil (2330 GO) a new dibenzoxa- the depth of depression was evaluated on zepin (Nitroxazepine hydrochloride) has Hamilton depressive rating scale. The dura­ been extensively studied during the last tion of trial was 4 weeks. Each patient was decade in animals and human beings for its clinically examined to exclude the presence antidepressant action with fairly good re- of any organic disease. Pregnant women, Milts (Hagadia cf ill 19f>8 and Tcja and Na- patients with prostatic hypertrophy and rang 197D). Some investigators (Desou/a those with history ot epilepsy were not int­ and Chowdhary 1974 and Gupta ct.il 1976) ituled in the study. liave been demonstrated superiority ot sin­ These patients were not given any anti­ tamil over imiprainine and trimipramine in depressant therapy tor atleast one week be­ relciving depressive symptoms. fore the commencement of trial. The cap­ Dexepin being a tricyclic compound, sules containing Sintamil and Doxcpine has its basic action similar to other com­ were identical in size, shape and colour ami pounds ot the group (Groton 1967). It is it was not known to investigator whether a tertiary amine like Amtriptyline and Imi­ particular patient was on Sintamil or Do­ prainine which has mood elevating proper­ xcpine. Both the Sintamil as well as Doxc- ties (Arieti 1975). Some workers have rated pin were administered at bed time. The pa­ it as good or slightly superior to Iniipramine tients were examined every week and fresh and Amitriptylme whereas Swiss psychia­ drug samples issued.
    [Show full text]
  • Antidepressant Treatment for Postnatal Depression
    This is a repository copy of Antidepressant treatment for postnatal depression. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/163986/ Version: Published Version Article: Brown, Jennifer Valeska Elli orcid.org/0000-0003-0943-5177, Wilson, Claire A., Ayre, Karyn et al. (5 more authors) (2020) Antidepressant treatment for postnatal depression. Cochrane Database of Systematic Reviews. CD013560. ISSN 1469-493X https://doi.org/10.1002/14651858.CD013560 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Cochrane Library Cochrane Database of Systematic Reviews Antidepressant treatment for postnatal depression (Protocol) Brown JVE, Wilson CA, Ayre K, South E, Molyneaux E, Trevillion K, Howard LM, Khalifeh H Brown JVE, Wilson CA, Ayre K, South E, Molyneaux E, Trevillion K, Howard LM, Khalifeh H. Antidepressant treatment for postnatal depression. Cochrane Database of Systematic Reviews 2020, Issue 3. Art. No.: CD013560. DOI: 10.1002/14651858.CD013560. www.cochranelibrary.com Antidepressant treatment for postnatal depression (Protocol) Copyright © 2020 The Cochrane Collaboration.
    [Show full text]
  • Beta Blockers Herbs
    Accredited Asthma, Allergy, & Food Intolerance Center • 1009B Dupont Square North • Louisville, KY • 40207 • Phone (502)895 -3330 • Fax (502)895-3356 IMPORTANT LIST OF MEDICATIONS TO AVOID - REVIEW IMMEDIATELY ANTIHISTAMINES ANTIHISTAMINES (CONT.) TRICYCLIC ANTIDEPRESSANTS **STOP 10 days PRIOR TO TESTING** **STOP 2 DAYS or 48 Hours PRIOR TO TESTING** **STOP 10 days PRIOR TO TESTING** GENERIC NAME BRAND NAME GENERIC NAME BRAND NAME **Please contact the ordering physician Azelastine Astelin Acrivastine Semprex-D before stopping these medications.** Azelastine Optivar Olopatadine Pataday Cetirizine Zyrtec GENERIC NAME BRAND NAME Chlorcyclizine HCl Ahist Amitriptyline Elavil Chlorcyclizine HCl Stahist Medications for Dizziness/Motion Amitriptyline Endep Chlorpheniramine Aller-Chlor Sickness Amitriptyline Etrafon Chlorpheniramine Chlo-Amine **STOP 10 DAYS PRIOR TO TESTING** Amitriptyline Laroxyl Chlorpheniramine Chlorphen GENERIC NAME BRAND NAME Amitriptyline Limbitrol Chlorpheniramine Chlor-Trimeton Meclizine Hydrochloride Antivert Amitriptyline Tryptizol Chlorpheniramine C.P.M. Meclizine Dramamine Amitriptyline Vanatrip Chlorpheniramine Effidac-24 Amitriptylinoxide Ambivalon Chlorpheniramine Ridraman Amitriptylinoxide Amioxid Cimetidine Tagamet Amitriptylinoxide Equilibrin Clemastine Allerhist-1 BETA BLOCKERS Amoxampine Asendin Clemastine Contac 12 Hour Allergy **DO NOT TAKE these medications the MORNING Butriptyline Evadyne Clemastine Tavist-1 OF your appointment** Clomipramine Anafranil Cyproheptadine Periactin GENERIC NAME BRAND NAME
    [Show full text]
  • Esketamine for the Treatment of Treatment-Resistant Depression: Effectiveness and Value
    Esketamine for the Treatment of Treatment-Resistant Depression: Effectiveness and Value Evidence Report May 9, 2019 Prepared for ©Institute for Clinical and Economic Review, 2019 The University of Illinois at Chicago College of ICER Staff and Consultants Pharmacy’s Center for Pharmacoepidemiology and Pharmacoeconomic Research* Steven J. Atlas, MD, MPH Daniel R. Touchette, PharmD, MA Associate Professor of Medicine Professor of Pharmacy Harvard Medical School, Boston Assistant Director, Center for Pharmacoepidemiology Director, Practice Based Research & Quality and Pharmacoeconomic Research Improvement University of Illinois at Chicago Division of General Internal Medicine Massachusetts General Hospital, Boston Nicole Boyer, PhD Research Fellow Foluso Agboola, MBBS, MPH University of Chicago Director, Evidence Synthesis Institute for Clinical and Economic Review Brian Talon, PharmD PhD Student University of Illinois at Chicago Katherine Fazioli Senior Research Assistant Bob G. Schultz, PharmD Institute for Clinical and Economic Review PhD Student and Research Fellow University of Illinois at Chicago Varun M. Kumar, MBBS, MPH, MSc Associate Director of Health Economics Institute for Clinical and Economic Review *The role of the University of Illinois at Chicago College of Ellie Adair, MPA Pharmacy’s Center for Pharmacoepidemiology and Program Manager Pharmacoeconomic Research is limited to the development of the cost-effectiveness model, and the resulting ICER reports do not Institute for Clinical and Economic Review necessarily represent the views of the UIC. David Rind, MD Chief Medical Officer Institute for Clinical and Economic Review Steve Pearson, MD, MSc President Institute for Clinical and Economic Review Date of Publication: May 9, 2019 Steven Atlas served as the lead author for the report.
    [Show full text]
  • Resistant Depression: Effectiveness and Value
    Esketamine for the Treatment of Treatment- Resistant Depression: Effectiveness and Value Draft Evidence Report March 21, 2019 Prepared for ©Institute for Clinical and Economic Review, 2019 The University of Illinois at Chicago College of ICER Staff and Consultants Pharmacy’s Center for Pharmacoepidemiology and Pharmacoeconomic Research* Steven J. Atlas, MD, MPH Daniel R. Touchette, PharmD, MA Associate Professor of Medicine Professor of Pharmacy Harvard Medical School, Boston Assistant Director, Center for Pharmacoepidemiology Director, Practice Based Research & Quality and Pharmacoeconomic Research Improvement University of Illinois at Chicago Division of General Internal Medicine Massachusetts General Hospital, Boston Nicole Boyer, PhD Research Fellow Foluso Agboola, MBBS, MPH University of Chicago Director, Evidence Synthesis Institute for Clinical and Economic Review Brian Talon, PharmD PhD Student University of Illinois at Chicago Katherine Fazioli Senior Research Assistant Bob G. Schultz, PharmD Institute for Clinical and Economic Review PhD Student and Research Fellow University of Illinois at Chicago Varun Kumar, MBBS, MPH, MSc Associate Director of Health Economics Institute for Clinical and Economic Review Ellie Adair, MPA Program Manager Institute for Clinical and Economic Review David Rind, MD Chief Medical Officer Institute for Clinical and Economic Review *The role of the University of Illinois at Chicago College of Pharmacy’s Center for Pharmacoepidemiology and Pharmacoeconomic Research is limited to the development of the Steve Pearson, MD, MSc cost-effectiveness model, and the resulting ICER reports do not President necessarily represent the views of the UIC. Institute for Clinical and Economic Review Date of Publication: March 21, 2019 Steve Atlas served as the lead author for the report.
    [Show full text]
  • Product Monograph
    PRODUCT MONOGRAPH Pr SILENOR® Doxepin tablets 3 and 6 mg doxepin as doxepin hydrochloride Hypnotic Paladin Labs Inc. Date of Preparation: 6111 Royalmount Ave. December 07, 2012 Montreal, Quebec H4P 2T4 Version : 1.3 Submission Control No: 152398 ® Trademark of Pernix Therapeutics LLC. SILENOR Product Monograph Page 1 of 30 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................8 DRUG INTERACTIONS ..................................................................................................13 DOSAGE AND ADMINISTRATION ..............................................................................15 OVERDOSAGE ................................................................................................................15 ACTION AND CLINICAL PHARMACOLOGY ............................................................17 STORAGE AND STABILITY ..........................................................................................19
    [Show full text]